Cizzle Biotechnology Holdings (LSE:CIZ) has had a US patent allowed by the USPTO covering core methods to measure the CIZ1B lung cancer biomarker, strengthening the licence position of Cizzle Bio as it prepares to commercialise the two‑step test in North America and the Caribbean.
The patent, titled "Use of a fibrinogen capture agent to detect a CIZ1B variant", protects a two‑step ELISA test format developed at the University of York; Cizzle Biotechnology, the UK‑based developer of diagnostic tests for early‑stage cancer, said the US grant follows a Canadian patent announced on 4 February and enhances protection in the key US market.
"Strengthening of the company's patent portfolio with this grant by the USPTO is timely and perfectly aligned with recent efforts to take the CIZ1B ELISA test format to market with our US partner Cizzle Bio," Dawn Coverley, Chief Scientific Officer of Cizzle Biotechnology, said.
The announcement states the test format is licensed to Cizzle Bio for use in North America and the Caribbean, giving the licensee the intellectual‑property position to progress commercial roll‑out and partner with specialist clinical laboratories and hospitals.
Cizzle also holds European Patent Office protection and said it intends to secure further licences with accredited facilities in the UK and Europe, including the NHS, to support wider clinical access.
The USPTO grant therefore positions Cizzle Bio as it prepares to launch the CIZ1B ELISA test and pursue partnerships to establish market presence.
